TITLE

Neoadjuvant Therapy for Esophageal Cancer: Standard of Care or Elusive Myth?

AUTHOR(S)
Boyle, M.J.; Franceschi, D.; Robinson, D.S.; Livingstone, A.S.
PUB. DATE
October 2001
SOURCE
American Surgeon;Oct2001, Vol. 67 Issue 10, p956
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Although surgical resection as the sole treatment modality for esophageal carcinoma has historically been associated with poor survival rates, improvements have recently been reported using varied neoadjuvant chemo-radiation protocols. This study evaluates the outcome of patients undergoing surgery for esophageal carcinoma at the University of Miami/Jackson Memorial Hospital between July 1991 and June 1996. Seventy-two patients underwent esophageal resection; 51 males and 21 females with a median age of 62.5 years (range = 42-82). Histology was equally distributed between adenocarcinoma (36 patients; 50%) and squamous cell carcinoma (36 patients; 50%). Pathological stage distribution consisted of 6 stage 0 (8%), 10 stage I (14%), 23 stage II (32%), 31 stage III (43%), and 2 stage IV (3%) lesions. Patients were divided into three groups according to the type of preoperative treatment; Group 1 (n = 44); surgery alone; Group 2 (n = 18); neoadjuvant 5-fluorouracil based chemotherapy, and Group 3 (n = 9); neoadjuvant 5-fluorouracil based chemotherapy in conjunction with external beam radiation (XRT). One patient received preoperative XRT alone. All survivors were followed for a minimum of 1 year and statistical analysis was performed using Kaplan-Meier curves, log-rank, and chi-square tests. In the 28 patients receiving any form of neoadjuvant therapy only one patient had a pathological complete response (CR) (3.5%). The overall 5 year and median survival rates were 18 per cent and 20.5 months (range = 0-73), respectively. Individual treatment group survival rates at 5 years were 28% for Group 1; 21% for Group 2; and 0% for Group 3, showing no survival difference between Groups 1 and 2; Group 3 fared significantly worse than the other two, probably as a result of the high operative mortality in this group. These results indicate that surgical resection continues to be an important treatment modality for esophageal carcinoma. Neoadjuvant chemotherapy in our exp...
ACCESSION #
5331251

 

Related Articles

  • Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Osaka, Y.; Takagi, Y.; Hoshino, S.; Tachibana, S.; Tsuchida, A.; Aoki, T. // Diseases of the Esophagus;Dec2006, Vol. 19 Issue 6, p473 

    The purpose of this study was to address the feasibility of combination chemotherapy of docetaxel and nedaplatin for recurrent esophageal cancer patients in an outpatient setting. Patients received docetaxel (30 mg/m2 intravenously) on day 1 and nedaplatin (40 mg/m2 intravenously) on...

  • Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Noguchi, T.; Moriyama, H.; Wada, S.; Takeno, S.; Wakisaka, M.; Mori, H.; Uchida, Y. // Diseases of the Esophagus;Jun2003, Vol. 16 Issue 2, p94 

    SUMMARY The prognosis of patients with T4 esophageal carcinoma is poor, and thus an effective treatment needs to be established. The present study assessed the effect of chemoradiotherapy (CRT), postoperative morbidity and mortality, and survival time in 41 patients with T4 esophageal carcinoma....

  • External validation of a risk score in the prediction of the mortality after esophagectomy for cancer. D'Journo, X. B.; Berbis, J.; Jougon, J.; Brichon, P.-Y.; Mouroux, J.; Tiffet, O.; Bernard, A.; de Dominicis, F.; Massard, G.; Falcoz, P. E.; Thomas, P.; Dahan, M. // Diseases of the Esophagus;Jan2017, Vol. 30 Issue 1, p1 

    This study was designed as an external evaluation of the Steyerberg score in the prediction of different categories of postoperative mortality after esophagectomy on a large nationwide database of thoracic surgeons. Data collection was obtained from the Epithor national database encompassing the...

  • A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Sanford, N. N.; Catalano, P. J.; Enzinger, P. C.; King, B. L.; Bueno, R.; Martin, N. E.; Hong, T. S.; Wo, J. Y.; Mamon, H. J. // Diseases of the Esophagus;Jul2017, Vol. 30 Issue 7, p1 

    Preoperative chemoradiotherapy (CRT) with carboplatin/paclitaxel has been shown to increase survival in patients with esophageal cancer, including gastroesophageal junction (GE) junction cancer, over surgery alone; however, there have been no studies comparing the different neoadjuvant CRT...

  • Short-term outcomes of robotic radical esophagectomy for esophageal cancer by a nontransthoracic approach compared with conventional transthoracic surgery. Mori, K.; Yamagata, Y.; Aikou, S.; Nishida, M.; Kiyokawa, T.; Yagi, K.; Yamashita, H.; Nomura, S.; Seto, Y. // Diseases of the Esophagus;Jul2016, Vol. 29 Issue 5, p429 

    Transthoracic esophagectomy ( TTE) is believed to have advantages for mediastinal lymphadenectomy in the treatment of resectable esophageal cancer despite its association with a greater incidence of pulmonary complications and postoperative mortality. Transhiatal esophagectomy is regarded as...

  • Intraoperative and postoperative risk factors for anastomotic leakage and pneumonia after esophagectomy for cancer. Goense, L.; van Rossum, P. S. N.; Tromp, M.; Joore, H. C.; van Dijk, D.; Kroese, A. C.; Ruurda, J. P.; van Hillegersberg, R. // Diseases of the Esophagus;Jan2017, Vol. 30 Issue 1, p1 

    Morbidity and mortality after esophagectomy are often related to anastomotic leakage or pneumonia. This study aimed to assess the relationship of intraoperative and postoperative vital parameters with anastomotic leakage and pneumonia after esophagectomy. Consecutive patients who underwent...

  • Safety and efficacy of endoscopic spray cryotherapy for esophageal cancer. Tsai, F. C.; Ghorbani, S.; Greenwald, B. D.; Jang, S.; Dumot, J. A.; McKinley, M. J.; Shaheen, N. J.; Habr, F.; Wolfsen, H. C.; Abrams, J. A.; Lightdale, C. J.; Nishioka, N. S.; Johnston, M. H.; Zfass, A.; Coyle, W. J. // Diseases of the Esophagus;Nov2017, Vol. 30 Issue 11, p1 

    Although surgery is traditionally the standard of care for esophageal cancer, esophagectomy carries significant morbidity. Alternative endoscopic therapies are needed for patients who are not candidates for conventional treatment. The objective of this study is to assess the safety, efficacy,...

  • Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Makino, T; Yamasaki, M; Miyazaki, Y; Wada, N; Takahashi, T; Kurokawa, Y; Nakajima, K; Takiguchi, S; Mori, M; Doki, Y // Diseases of the Esophagus;Apr2018, Vol. 31 Issue 4, pN.PAG 

    SUMMARY: Although no consensus is available on the treatment of esophageal squamous cell carcinoma (ESCC) invading adjacent organs (T4), establishing effective induction treatments is crucial to altering an unresectable status and achieving curative resection. Here, we evaluated the efficacy of...

  • A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy. Mizota, Ayako; Shitara, Kohei; Kondo, Chihiro; Nomura, Motoo; Yokota, Tomoya; Takahari, Daisuke; Ura, Takashi; Muro, Kei // Oncology;2011, Vol. 81 Issue 3/4, p237 

    Objective: To retrospectively compare docetaxel (DTX) with paclitaxel (PTX) with regard to efficacy and safety in advanced or recurrent esophageal cancer patients who previously received platinum-based chemotherapy. Methods: We retrospectively analyzed 124 advanced or recurrent esophageal cancer...

  • Short-term prophylaxis with cetotaxime for prostatic surgery. Hargreave, T.B.; Hindmarsh, J.R.; Elton, R.; Chisholm, G.D.; Gould, J.C. // British Medical Journal (Clinical Research Edition);4/3/1982, Vol. 284 Issue 6321, p1008 

    Examines the reduction of post-operative complications through the use of parenteral cephalosphorin cefotaxime. Comparison between the treated and non-treated patients in the incidence of complications and episodes of febrile and tachycardia; Absence of differences in postoperative urea and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics